Grant: Doctoral: Vanier Canada Graduate Scholarships
University of Toronto
$150,000.00
SUrgical and Pharmacological novel intERventions to Improve Overall Results of Saphenous Vein Graft patency in coronary artery bypass grafting surgery. The "SUPERIOR SVG" Study: An International Multi-centred Randomized Controlled Clinical Trial
EF 2011-12
Résumé
Background: Ischemic heart disease (IHD) due to coronary artery blockages is the leading cause of death in the world. Coronary artery bypass surgery (CABG) improves survival and symptoms in patients with extensive coronary obstructions; in 2008, almost 15,000 Canadians underwent CABG. The saphenous vein (SVG) harvested from the leg is the most frequently used graft to bypass blockages on the heart. Unfortunately, 15-25% of all bypassed SVGs become diseased and fail within first year after surgery, increasing the risk of another heart attack or death. Injury to a layer of the SVG called the endothelium during surgery is a sentinel event for future vein graft disease after surgery. This trial investigates whether a novel surgical technique of vein harvesting, called the 'No-Touch' technique, which minimizes endothelium injury along with a daily fish oil supplement, can improve 1 year failure rates of the SVG, compared to conventional harvesting techniques and no fish oil supplement (placebo).
Method: This trial involves multiple surgical centers. Eligible CABG patients will undergo conventional(C) or no-touch technique(NT) and receive placebo(P) or a 2-gram fish-oil supplement per day(FO) for 1-year following surgery. The trial's design randomly puts each patient into one of four categories: NT+FO(Group A); NT+P(Group B); C+FO(Group C); C+P(Group D). At end of 1-year, each patient will undergo a CAT scan and clinical follow-up to determine graft failure rates and incidence of any major adverse cardiac events (MACE).
Hypothesis: We believe that vein graft failure and MACE rates will be lowest in Group A, intermediate in Groups B, C, and highest in D.
Clinical Impact: If our hypotheses are true, then patients undergoing CABG may have a better quality of life, require less cardiac procedures, and live longer. This has the potential to change current surgical practice, post-operative care, and improve lives of many patients undergoing CABG in Canada and world-wide.
Programme
Doctoral: Vanier Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
247812
Name
Deb Saswata
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Clinical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
SUrgical and Pharmacological novel intERventions to Improve Overall Results of Saphenous Vein Graft patency in coronary artery bypass grafting surgery. The "SUPERIOR SVG" Study: An International Multi-centred Randomized Controlled Clinical Trial
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Coronary Artery Bypass Grafting; Double Blinded; Fish Oil; Graft Patency; International Multi-Centered; No-Touch Vein Harvesting; Placebo; Randomized Clinical Trial; Saphenous Vein Graft
Abstract
Background: Ischemic heart disease (IHD) due to coronary artery blockages is the leading cause of death in the world. Coronary artery bypass surgery (CABG) improves survival and symptoms in patients with extensive coronary obstructions; in 2008, almost 15,000 Canadians underwent CABG. The saphenous vein (SVG) harvested from the leg is the most frequently used graft to bypass blockages on the heart. Unfortunately, 15-25% of all bypassed SVGs become diseased and fail within first year after surgery, increasing the risk of another heart attack or death. Injury to a layer of the SVG called the endothelium during surgery is a sentinel event for future vein graft disease after surgery. This trial investigates whether a novel surgical technique of vein harvesting, called the 'No-Touch' technique, which minimizes endothelium injury along with a daily fish oil supplement, can improve 1 year failure rates of the SVG, compared to conventional harvesting techniques and no fish oil supplement (placebo).
Method: This trial involves multiple surgical centers. Eligible CABG patients will undergo conventional(C) or no-touch technique(NT) and receive placebo(P) or a 2-gram fish-oil supplement per day(FO) for 1-year following surgery. The trial's design randomly puts each patient into one of four categories: NT+FO(Group A); NT+P(Group B); C+FO(Group C); C+P(Group D). At end of 1-year, each patient will undergo a CAT scan and clinical follow-up to determine graft failure rates and incidence of any major adverse cardiac events (MACE).
Hypothesis: We believe that vein graft failure and MACE rates will be lowest in Group A, intermediate in Groups B, C, and highest in D.
Clinical Impact: If our hypotheses are true, then patients undergoing CABG may have a better quality of life, require less cardiac procedures, and live longer. This has the potential to change current surgical practice, post-operative care, and improve lives of many patients undergoing CABG in Canada and world-wide.
Competitiondate
201111
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Deb, Saswata
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~